Vitura Health (ASX:VIT) ROE % Adjusted to Book Value: -4.08% (As of Dec. 2025)


What is Vitura Health ROE % Adjusted to Book Value?

Vitura Health ASX:VIT ROE % Adjusted to Book Value is -4.08% as of Dec. 2025. The stock has 8 warning signs investors should review.

Vitura Health's ROE % for the quarter that ended in Dec. 2025 was -3.55%. Vitura Health's PB Ratio for the quarter that ended in Dec. 2025 was 0.87. Vitura Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -4.08%.

Vitura Health ROE % Adjusted to Book Value Related Terms

Vitura Health ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vitura Health's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitura Health ROE % Adjusted to Book Value Chart

Vitura Health Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -24.39 6.42 5.53 7.44 8.99

Vitura Health Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 0.98 7.30 8.56 -4.08

ASX:VIT vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitura Health ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vitura Health's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vitura Health's ROE % Adjusted to Book Value falls into.


Vitura Health ROE % Adjusted to Book Value Calculation

Vitura Health's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=7.64% / 0.85
=8.99%

Vitura Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-3.55% / 0.87
=-4.08%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -4.08% mean?
Vitura Health (ASX:VIT) has a ROE % Adjusted to Book Value of -4.08% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vitura Health and its competitors.
Is Vitura Health's ROE % Adjusted to Book Value too high?
Vitura Health's current ROE % Adjusted to Book Value is -4.08%.
How does Vitura Health's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Vitura Health's ROE % Adjusted to Book Value of -4.08% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vitura Health and its competitors. Vitura Health's current ROE % Adjusted to Book Value is -4.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 73% below its estimated fair value. The current ROE % Adjusted to Book Value is -4.08%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current ROE % Adjusted to Book Value is -4.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitura Health Business Description

Address 299 Toorak Road, Suite 8, Level 3, South Yarra, VIC, AUS, 3141
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.